Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iMetal Resources Inc. stock logo
IMR
iMetal Resources
C$0.14
-6.9%
C$0.18
C$0.13
C$0.33
C$757K1.5940,126 shs226,400 shs
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
$5.10
-6.9%
$4.19
$2.92
$699.19
$2.91M-0.11109,129 shs100,814 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$1.52
-5.0%
$2.26
$0.82
$3.10
$121.00M-0.21550,476 shs474,573 shs
RTI International Metals Inc stock logo
RTI
RTI International Metals
$0.00
$0.00
$0.00
N/AN/AN/AN/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iMetal Resources Inc. stock logo
IMR
iMetal Resources
-6.90%-10.00%-6.90%-38.64%-57.81%
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
-6.93%-2.30%+14.86%-30.45%-98.87%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
-5.00%-4.40%-44.32%-35.04%+28.81%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
iMetal Resources Inc. stock logo
IMR
iMetal Resources
N/AN/AN/AN/AN/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/AN/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.0404 of 5 stars
3.53.00.00.03.30.01.9
RTI International Metals Inc stock logo
RTI
RTI International Metals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iMetal Resources Inc. stock logo
IMR
iMetal Resources
0.00
N/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
0.00
N/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$15.00886.84% Upside
RTI International Metals Inc stock logo
RTI
RTI International Metals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iMetal Resources Inc. stock logo
IMR
iMetal Resources
N/AN/AC$0.04 per share3.51C$0.91 per shareN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/AN/A($61.61) per shareN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$59.76M2.02$0.09 per share17.80$0.47 per share3.23
RTI International Metals Inc stock logo
RTI
RTI International Metals
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iMetal Resources Inc. stock logo
IMR
iMetal Resources
-C$2.26M-C$0.43N/AN/AN/A-37.31%-20.97%N/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
-$51.16MN/A0.00N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.04N/A4.90N/A-21.03%-30.89%-11.74%N/A
RTI International Metals Inc stock logo
RTI
RTI International Metals
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest IMR, RTI, PBM, and PLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A-$0.05N/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iMetal Resources Inc. stock logo
IMR
iMetal Resources
N/A3.01%N/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
RTI International Metals Inc stock logo
RTI
RTI International Metals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iMetal Resources Inc. stock logo
IMR
iMetal Resources
0.15
0.13
7.79
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/A
0.64
0.64
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27
RTI International Metals Inc stock logo
RTI
RTI International Metals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
iMetal Resources Inc. stock logo
IMR
iMetal Resources
N/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
77.44%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%
RTI International Metals Inc stock logo
RTI
RTI International Metals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
iMetal Resources Inc. stock logo
IMR
iMetal Resources
1405.61 millionN/ANot Optionable
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/A570,0006.36 millionN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20079.61 million69.00 millionOptionable
RTI International Metals Inc stock logo
RTI
RTI International Metals
N/AN/AN/ANot Optionable

Recent News About These Companies

RTI INTERNATIONAL METALS (NYSE: RTI) - Share Price and Research
Research Urges Tyre Particles as Unique Eco Threat

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
iMetal Resources stock logo

iMetal Resources CVE:IMR

C$0.14 -0.01 (-6.90%)
As of 06/5/2025 03:46 PM Eastern

iMetal Resources Inc., a junior exploration company, focuses on the acquisition, exploration, development, and evaluation of resource properties in Ontario and Quebec in Canada. The company explores for precious and base metal resources. Its flagship property is the Gowganda West project covering an area of approximately 147 squares kilometers located in Ontario; Kerrs Gold property covering an area of 665 hectares located in Ontario; and Ghost Mountain property consists of eleven claim units covering an area of 220 hectares located in Ontario. The company also holds 100% interest in the Carheil project encompasses approximately 5,400 acres of contiguous land located in the Abitibi region of Quebec. The company was formerly known as Adroit Resources Inc. and changed its name to iMetal Resources Inc. in November 2015. iMetal Resources Inc. was incorporated in 1993 and is headquartered in Vancouver, Canada.

Psyence Biomedical stock logo

Psyence Biomedical NASDAQ:PBM

$5.10 -0.38 (-6.93%)
Closing price 06/5/2025 03:59 PM Eastern
Extended Trading
$5.13 +0.03 (+0.59%)
As of 06/5/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$1.52 -0.08 (-5.00%)
Closing price 06/5/2025 04:00 PM Eastern
Extended Trading
$1.52 -0.01 (-0.33%)
As of 06/5/2025 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

RTI International Metals stock logo

RTI International Metals NYSE:RTI

RTI International Metals, Inc. is a producer and global supplier of titanium mill products and a manufacturer of fabricated titanium and specialty metal components for the national and international aerospace, defense, energy, medical device, and other consumer and industrial markets. The Company operates in two segments: the Titanium segment and Engineered Products and Services (EP&S) segment. The Titanium Segment melts, processes, produces, forges, stocks, distributes, finishes, cuts-to-size, and facilitates just-in-time delivery services of a complete range of titanium mill products, which are further processed by its customers for use in a variety of commercial aerospace, defense, and industrial and consumer applications. The EP&S Segment is comprised of companies with significant hard and soft-metal expertise that form, extrude, fabricate, machine, additively manufacture, micro-machine, and assemble titanium, aluminum, and other specialty metal parts and components.